New adoptive immunotherapy strategies for solid tumours with CIK cells

Expert Opinion on Biological Therapy

Volumn 12, Issue 5, 2012, Pages 565-572

  Thanendrarajan, Sharmilan ^a   Kim, Young ^a   Schmidt Wolf, Ingo ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

cancer treatment; CIK cells; cytokine; dendritic cells; immunotherapy; T cells

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOKINE; DENDRITIC CELL VACCINE; DOCETAXEL; INTERLEUKIN 2; SORAFENIB; TEMOZOLOMIDE;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CHEMOEMBOLIZATION; CHILL; COLON ADENOCARCINOMA; CYTOKINE INDUCED KILLER CELL; CYTOLYSIS; CYTOTOXICITY; DISEASE FREE SURVIVAL; EX VIVO STUDY; FEVER; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INOPERABLE CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MINIMALLY INVASIVE PROCEDURE; NONHUMAN; RADIOFREQUENCY ABLATION; REVIEW; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE; TUMOR CELL;

CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; NEOPLASMS;

EID: 84859570163     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.668879     Document Type: Review

References (38)

1. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-93
2. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011;2:363-8
3. Helms MW, Prescher JA, Cao YA, et al. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010;59:1325-34
4. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010;2010:435745
5. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21:1673-9 (Pubitemid 24223014)
6. Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 1995;86:3493-9
7. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139-49 The first report on ex vivo generation of CIK cells that revealed cytolytic activity against human lymphoma cell line in vivo.
8. Nishimura R, Baker J, Beilhack A, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008;112:2563-74
9. Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994;87:453-8 This manuscript is groundbreaking for the generation of large amounts of CIK cells. The timed addition of IFN-γ, IL-1, IL-2 and an mAb against CD3 leads to a massive expansion of CIK cells.
10. Zoll B, Lefterova P, Csipai M, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 1998;47:221-6 (Pubitemid 29009677)
11. Wang Y, Dai H, Li H, et al. Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol 2011;2011:621414
12. Kim YJ, Lim J, Kang JS, et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res 2010;33:1789-95
13. Kim HM, Kang JS, Lim J, et al. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res 2009;32:781-7
14. Kim HM, Lim J, Park SK, et al. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 2007;7:1802-7 (Pubitemid 350054928)
15. Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004;10:1146-51 (Pubitemid 38559390)
16. Su X, Zhang L, Jin L, et al. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biother Radiopharm 2010;25:465-70
17. Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009;27:130-9
18. Jin J, Joo KM, Lee SJ, et al. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep 2011;25:33-9
19. Liu P, Chen L, Huang X. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm 2009;24:91-8
20. Huang X, Chen YT, Song HZ, et al. Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 2011;17:3002-11
21. Jiang JT, Shen YP, Wu CP, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010;16:6155-62
22. Wu C, Jiang J, Shi L, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008;28:3997-4002 A description of combing CIK cells with conventional chemotherapy in advanced NSCLC leading to longer PFS and OS.
23. Zhao Q, Zhang H, Li Y, et al. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res 2010;9:118
24. Niu Q, Wang W, Li Y, et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in thetreatment of advanced solid malignancies. Int Immunopharmacol 2011;11:449-56
25. Hao MZ, Lin HL, Chen Q, et al. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chin J Cancer 2010;29:172-7 A description of combining CIK cells with TACE in HCC patients leading to higher PFS and OS.
26. Zhao M, Wu PH, Zeng YX, et al. Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial. Zhonghua Yi Xue Za Zhi 2006;86:1823-8 (Pubitemid 44295480)
27. Zhao G, Huang Y, Ye L, et al. Therapeutic efficacy of traditional vein chemotherapy and bronchial arterial infusion combining with CIKs on III stage non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009;12:1000-4
28. Flieger D, Kufer P, Beier I, et al. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM expressing tumor cells. Cancer Immunol Immunother 2000;49:441-8
29. Zhang D, He JT. In vitro cytotoxicity effects of cocultured DC-CIK cells combined with sorafenib against hepatocellular carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011;27:664-7
30. Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokine induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res 2011;35:1136-42
31. Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001;24:502-10 The authors provide a detailed description of the interaction between CIK cells and DCs. (Pubitemid 33104869)
32. Wang H, Zhou FJ, Wang QJ, et al. Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma - a report of ten cases. Ai Zheng 2006;25:625-30
33. Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009;11:1076-83 A description of clinical application of DC-activated CIK cells in patients with NSCLC resulting in higher 2-year OS rate.
34. Zhong R, Teng J, Han B, et al. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011;60:1497-502
35. Finke S, Trojaneck B, Lefterova P, et al. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther 1998;5:31-9 First report on cytokine gene transfection in CIK cells resulting in higher proliferation rate and antitumour activity. (Pubitemid 28045067)
36. Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999;81:1009-16 The first clinical application of autologous CIK cells in patients with solid and haematological malignancies. The study revealed a considerable antitumour activity with a minimal toxicity profile. (Pubitemid 29516145)
37. Yu X, Xia W, Zhang T, et al. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells. Int J Hematol 2010;92:276-82
38. Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137:305-10 First report of an IRCC for reports on clinical use of CIK cells.